As Mission Pharmacal’s president of commercial operations, Terrell Herring oversees strategy and brand positioning for the company. In addition, he focuses on product development and key new hires. Under Terrell Herring’s leadership, Mission Pharmacal also has succeeded in forging profitable new partnerships. At the beginning of 2018, Mission Pharmacal announced that it had established a partnership with Fabre-Kramer Pharmaceuticals, Inc., on a project to manufacture the antidepressant medication Travivo in extended-release tablet form. Travivo (generic name Gepirone HCL) is designed to treat generalized anxiety disorder. The two companies have elected to facilitate the transfer of the Fabre-Kramer technology to Mission for the making of registration batches of Travivo. Travivo’s advantages include its ability to function in the body without causing the types of chemical dependency, amnesia, and sexual dysfunctions that are often among the common side-effects of competing products. After Mission produces the registration batches, executives will submit the associated data to the US Food and Drug Administration as part of the agency’s review and approval process. Following anticipated FDA approval, Mission and Fabre-Kramer will focus on their joint agreement for Mission’s ongoing production of Travivo.
0 Comments
Terrell Herring serves as president of Alamo Pharma Services, a subsidiary company of Mission Pharmacal. At the latter firm, he additionally assists in directing strategic decision-making as commercial operations president. Terrell Herring and Alamo Pharma recently announced the company’s participation in a major Washington, DC conference designed to better acquaint attendees with how government regulatory processes affect innovations in the pharmaceutical industry. Alamo Pharma served as a sponsor of the FDA/CMS Summit, held toward the close of 2017. In addition, the company’s chief operating officer Peter Marchesini spoke as a member of a panel discussing the future of product-related communications, with specific reference to off-label developments. Mr. Marchesini’s panel group was moderated by journalist M. Nielsen Hobbs, whose decades of experience have informed his coverage of the pharmaceutical industry. The panel discussed the ongoing needs for training of company representatives in product knowledge and compliance requirements, and for overall fairness in labeling. KNect365, part of the Informa family of companies, hosted the summit, which also provided corporate leaders the opportunity to connect directly with regulators on issues involving formulary protocols. A biology graduate from The Citadel, Military College of South Carolina, Terrell “Terry” Herring has served as president of commercial operations at Mission Pharmacal since 2010. A resident of Pennsylvania, Terrell Herring was recognized by PharmaVOICE among its 2017 Red Jacket honorees. PharmaVOICE Red Jacket honorees are individuals that are selected by their colleagues, peers, and even competitors among the PharmaVOICE 100 multiple times. They are passionate men and women drawn from the entire life sciences industry including pharmaceuticals, biopharmaceutical, biotechnology, clinical research, patient education, advertising, and academia, who have raised the bar with regard to exemplary industry practice and leadership. They challenge others, disrupt the status quo, and focus on the long-term vision of better health outcomes, not short-term profits. Launched in 2014, the coveted Red Jacket list, widely referred to as the industry’s Hall of Fame, includes honorees like: -Nicholas Colucci, president of Publicis Healthcare Communications Group, a leading healthcare communications platform -Jeffrey Berkowitz, president of Walgreens Boots Alliance Development GmbH which provides solutions to the global challenges pharmaceuticals face -Amir Kalali, MD, vice president and global head of Neuroscience Center of Excellence. Amir is widely respected in the life sciences industry for his expertise in fast-tracking product development through innovation and strategic collaboration. As commercial operations president for Texas-based Mission Pharmacal and president of the Mission subsidiary Alamo Pharma Services, Terrell Herring provides market-focused, strategic leadership to the companies’ teams. Honored with a 2017 Red Jacket by the industry resource PharmaVOICE, Terrell Herring is also a philanthropist, whose long-lasting commitment to the nonprofit group A New Equilibrium includes current service on its board of directors. A New Equilibrium, or ANE, brings business executives together to support one another in creating balance, personal and professional integrity, and a greater spiritual focus in their lives. The organization’s core values include the insight that an individual’s intentional spiritual development provides him or her with the ability to become a better, more effective, and more inspiring leader. On its website, ANE promotes a range of associated resources, including the 2012 book The Joy of Work: How to Stay Calm, Confident and Collected in a Chaotic World. Written by executive coach Stephen G. Payne, the book has garnered praise as an informative tool for executives who want to increase their abilities to get more out of work and life, and to make a lasting difference. Its emphasis on powering one’s own inner drive for integrity and achievement has proven a life-changing message for a wide range of readers. The president of Alamo Pharma Services, Terrell “Terry” Herring provides strategic leadership for all aspects of the company’s operations. Also the president of commercial operations at Mission Pharmacal Company, Terrell Herring works with a dedicated team to fulfill unmet healthcare needs in the country. One of these needs is prenatal vitamins. Less than half of pregnant women in the United States take prenatal vitamins before pregnancy, according to research conducted by The Harris Poll and sponsored by March of Dimes. The research, summarized in a report titled Prenatal Health & Nutrition Survey, queried over 1,000 women between the ages of 18 and 45. The survey was conducted online. Researchers found that only 34 percent of women took multivitamins before finding out they were pregnant. The number was lower for Hispanic women (27 percent) and African-American women (10 percent). This is very alarming, since almost 50 percent of pregnancies in the country are unplanned and many birth defects, such as neural tube defects (NTDs), occur in the first month of pregnancy. This means that women who do not take enough NTD-preventing multivitimins with folic acid before pregnancy and in its early stages have a higher likelihood of giving birth to babies with NTDs. Researchers found two reasons for the late uptake of prenatal vitamins. The first was a lack of public education on the importance of multivitamins before pregnancy. The second was the cost of prenatal care, especially among Hispanic women. Mission Pharmacal Company is working to ensure as many women get access to critical multivitamins before and during pregnancy as possible. In addition to serving as president of commercial operations at Mission Pharmacal, Terrell “Terry” Herring is active with the subsidiaries Alamo Pharma Services, BexR Logistix, BioComp Pharmaceuticals, Epic Fulfillment, Integrus Pharmaceuticals, and ProSolus Pharma. Alongside his activities with the Mission Family of Companies, Terrell Herring serves on the Advisory Board of BioAgilytix, one of the world’s leading bioanalytical testing laboratories. Thanks to a recent expansion of the laboratory at its US headquarters, BioAgilytix now has the capability to accommodate even the largest Phase III bioanalytical studies. The expansion added nearly 21,000 square feet to the North Carolina-based facility, which now features over 48,000 square feet of state-of-the-art lab space. BioAgilytix, which specializes in large molecule analysis, designed the expansion to improve its capacity and technology for studies involving components such as cell-based assays, biomarkers, and immunogenicity. During the build-out, the company also focused on maintaining its status as one of the industry’s leading Good Manufacturing Practice facilities, a distinction that displays its commitment to upholding quality standards and industry best practices. Terrell Herring leverages over 30 years of experience in the pharmaceutical industry to serve as president of commercial operations at Mission Pharmacal, where he develops strategy and plays a key role in decisions ranging from new product offerings to upper-level hiring and placements. Terrell Herring’s pharmaceutical experience also assists him in other professional endeavors, including his service on the Advisory Board of BioAgilytix. With headquarters in Hamburg, Germany, and Durham, North Carolina, BioAgilytix is a biological testing laboratory that specializes in large molecule bioanalysis. Its team comprises scientific and QA professionals who provide a wide range of bioanalytical services to assist clients at every phase of the study process, from preclinical and discovery work to phase I through phase IV trials, ensuring regulatory compliance each step of the way. One of the company’s many services is pharmacokinetics assessment. Pharmacokinetics (PK) focuses on the human body’s reaction to a given pharmaceutical, from ingestion through absorption, distribution, metabolism, and ultimately excretion. PK assessment of a given pharmaceutical helps shed light on its efficacy as well as its interaction with the body, and assists pharmaceutical companies in determining drug safety and dosage specifications. BioAgilytix provides PK assessment support across a range of species studies and in multiple formats, such as plasma, urine, saliva, and serum. President of commercial operations for Mission Pharmacal Company Terrell Herring is an established pharmaceutical marketing executive. In addition to his day job, Terrell “Terry” Herring serves as a board member for several organizations, including BioAgilytix. BioAgilytix provides large molecule global studies performed by researchers from around the world. The company has become a preferred bioanalytical laboratory for many companies in the biotech and pharma fields, offering services in areas such as pharmacokinetics. Pharmacokenetics helps determine how the human body reacts to various pharmaceuticals. This is essential to determining a drug’s safety and effectiveness. The pharmacokinetic assay procedures used by BioAgilytix comply with international regulations and regulatory standards, including FDA guidelines for industry regarding population pharmacokenetics. The population pharmacokenetics process helps identify the differences between - and effectiveness in - a drug’s effect on population subgroups. The FDA guidelines give researchers more information on when a population study should be performed as well as how to execute the study and what parameters to use. Due to constant changes and effectiveness in subgroups, constant communication is required between the FDA review staff and sponsors of a given study. A former executive with InVentiv Health, Terrell "Terry" Herring has served as president of commercial operations for Mission Pharmacal Company since 2010. In addition to his role with Mission, Terrell "Terry" Herring serves on the advisory board for BioAgilytix, a bioanalytical testing laboratory with locations in North Carolina and Germany. A major area of focus for BioAgilytix is gene therapy and its growing prevalence as a treatment option for diseases such as cancer, Parkinson's, Alzheimer's, and diabetes. Over 200 gene therapy products for cancer were in commercial development as of 2016, while the total number of in-development gene therapy products doubled from 2012 to 2015. The therapy works by using sections of DNA to initiate genetic material into the cells of a patient. The resulting DNA carries a functioning gene which corrects the effects of a particular disease-causing mutation. The adeno-associated virus (AAV) is most commonly used as a carrier to deliver genes to the cells. BioAgilytix's scientists have a wealth of experience analyzing AAV gene therapy options, while the company invests in a variety of platforms used by its customers to facilitate innovation in the field. A graduate of the Military College of South Carolina (the Citadel), Terrell “Terry” Herring is a successful pharmaceutical industry executive and entrepreneur. Currently, Terrell Herring applies his expertise as the president of Mission Pharmacal and Alamo Pharma Services, where he provides daily strategic leadership. Founded in 1946, Mission Pharmacal is a privately held, San Antonio-based pharmaceutical company. Since its inception, the firm has actively delivered prescription and over-the-counter drugs and supplements to consumers to help improve their lives. Throughout its first seven decades, the company has grown and diversified to include seven firms known as the Mission Family of Companies. Among these are: - Alamo Pharma Services – an outsourced sales organization founded in 2011. - BioComp Pharma – a subsidiary that was founded in 2009 to focus on the commercialization of generic drugs. - Prosolus – a subsidiary acquired in 2015 that develops and manufactures transdermal and trans-mucosal drug delivery products - Espada Dermatology - a consumer dermatology division. - BexR Logistix – a third party logistics firm that serves multiple industries. - EPIC Fulfillment - a subsidiary of BexR and the warehousing arm of Mission. |
AuthorTerrell Herring began working at Mission Pharmacal Company in 2010, bringing more than 25 years of experience in the pharmaceutical industry to his role as President of Commercial Operations. Archives
February 2018
Categories
All
|